Alembic Pharmaceuticals: Receives USFDA Final Approval for Venetoclax Tablets, 10 mg, 50 mg and 100 mg
Alembic Pharmaceuticals (APLLTD) filed a disclosure titled "Receives USFDA Final Approval for Venetoclax Tablets, 10 mg, 50 mg and 100 mg". The company is valued at about ₹15,387 crore.
What happened
Alembic Pharmaceuticals (APLLTD) filed a disclosure with the exchanges on 30 October 2026 at 06:28 PM titled "Receives USFDA Final Approval for Venetoclax Tablets, 10 mg, 50 mg and 100 mg".
Company snapshot
Alembic Pharmaceuticals is a small-cap company in the Healthcare sector, with a market value of about ₹15,387 crore.
The stock last traded at ₹782.8, against a 52-week range of ₹635.8–₹998 (21.6% below the high).
Before this filing the shares had moved −9.4% over the month and −3.6% over three months. Average daily turnover over the last 20 sessions was about ₹12.93 crore.
Promoters held 69.87% at the end of Q1 FY27, up 0.13% points from the previous quarter. Foreign institutions owned 4.18% and domestic institutions 15.94%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 1,711 | 154.4 | 7.85 |
| Q2 FY26 | 1,910 | 184.7 | 9.4 |
| Q3 FY26 | 1,876 | 133 | 6.76 |
| Q4 FY26 | 1,848 | 201.5 | 10.31 |
| Q1 FY27 | 2,150 | 173.1 | 8.8 |
What history shows
BCEIE's records show 12 or more previous approval filings from the company since May 2026.
After those filings, the stock gained 1.3% on average the next trading day and was up 3.4% on average after five days (10 filings with price data).
Across 111 similar disclosures by other Healthcare companies, shares moved +0.4% on average the next day and +0.9% over five days; 50% of them rose the next day.
Market-wide, 1,541 approval filings with an impact score of 50 or more saw an average next-day move of +0.1%, with 47% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 19 Oct 2026 | Herewith the Intimation under Regulation 30 of SEBI LODR… | −1.1% | — |
| 17 Oct 2026 | Alembic Pharmaceuticals Limited receives USFDA Final Approval for… | −0.2% | — |
| 16 Sept 2026 | Update on USFDA inspection conducted during 3rd March, 2025 to 7th… | +2.5% | +3.0% |
| 11 Sept 2026 | Successful completion of unannounced USFDA onsite inspection at… | −0.7% | +3.6% |
| 7 Sept 2026 | Approval | +2.2% | +3.2% |
What to watch
- 4 November 2026: Board meeting — Financial Results/Other business matters.
In the news
Recent coverage elsewhere (links open the original publisher):
- Alembic Pharmaceuticals Limited Estimates – NSE:APLLTD
- Pradeep Jain Appointed Associate Vice President – Accounts & Finance at Alembic Pharmaceuticals
- Alembic Pharmaceuticals Gets USFDA Final Approval For Ear Infection Drug
- Alembic Pharmaceuticals Receives USFDA Final Approval for Ciprofloxacin and Dexamethasone Ear Suspension
- Alembic Pharmaceuticals secures USFDA final approval for Valganciclovir oral solution
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.